188 related articles for article (PubMed ID: 28923044)
1. Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.
Anyakora C; Ekwunife O; Alozie F; Esuga M; Ukwuru J; Onya S; Nwokike J
BMC Health Serv Res; 2017 Sep; 17(1):665. PubMed ID: 28923044
[TBL] [Abstract][Full Text] [Related]
2. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
Tauqeer F; Myhr K; Gopinathan U
Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
[TBL] [Abstract][Full Text] [Related]
3. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
4. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organ Tech Rep Ser; 2003; 917():i-viii, 1-125, back cover. PubMed ID: 15024913
[TBL] [Abstract][Full Text] [Related]
5. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management.
Vinther A; Ramnarine E
PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505
[TBL] [Abstract][Full Text] [Related]
6. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
[TBL] [Abstract][Full Text] [Related]
7. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
8. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
[TBL] [Abstract][Full Text] [Related]
9. Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.
Gemal A; Keravec J; Menezes A; Trajman A
BMC Public Health; 2013 Mar; 13():279. PubMed ID: 23537151
[TBL] [Abstract][Full Text] [Related]
10. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
[TBL] [Abstract][Full Text] [Related]
11. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization Expert Committee on Specifications for Pharmaceutical Preparations
World Health Organ Tech Rep Ser; 2003; 908():i-viii, 1-136, back cover. PubMed ID: 12768889
[TBL] [Abstract][Full Text] [Related]
12. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
Steinwandter V; Herwig C
PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
[TBL] [Abstract][Full Text] [Related]
13. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
14. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
[TBL] [Abstract][Full Text] [Related]
15. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2012; (970):1-235, back cover. PubMed ID: 22894011
[TBL] [Abstract][Full Text] [Related]
16. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Srai JS; Badman C; Krumme M; Futran M; Johnston C
J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
[TBL] [Abstract][Full Text] [Related]
17. An assessment of adherence to the WHO-delineated good manufacturing practice by the pharmaceutical companies in Kabul, Afghanistan.
Roien R; Shrestha R; Yadav K; Ozaki A; Ahmadi MB; Kaneda Y; Kotera Y; Sapkota B; Shrestha S
Cost Eff Resour Alloc; 2022 Apr; 20(1):17. PubMed ID: 35366905
[TBL] [Abstract][Full Text] [Related]
18. Characteristics, risk management and GMP standards of pharmaceutical companies in China.
Chen H; Qin L; Jiang C; Qin M; Sun Y; Luo J
Front Public Health; 2023; 11():1103555. PubMed ID: 36969675
[TBL] [Abstract][Full Text] [Related]
19. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2011; (961):1-428, back cover. PubMed ID: 21699061
[TBL] [Abstract][Full Text] [Related]
20. Crossing the fourth hurdle.
Rawlins MD
Br J Clin Pharmacol; 2012 Jun; 73(6):855-60. PubMed ID: 22404227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
